AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$PRGO

Perrigo Q3 2026 slides show sequential gains amid portfolio shift

Perrigo (NYSE:PRGO) reported Q3 2026 earnings with adjusted EPS of $0.60, beating estimates, while revenue of $989M missed expectations. The stock rose 4.62% to $16.43. Despite year-over-year declines, sequential improvements were noted in sales and margins. The company announced a divestiture of its Infant Formula business for $40M upfront and up to $135M in milestones, part of its strategic transformation.

Original reporting
investing.com
Published Nov 4, 2026, 2:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PRGO
Bullish
high confidence
Mentioned
$PRGO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PRGOBullishHigh
01

Why it matters

The earnings beat and margin improvement suggest the Three‑S Plan is delivering early results, supporting a bullish outlook.

02

Market read

First‑time earnings release with beat on EPS and margin expansion, driving a notable stock move.

03

What to watch

Contingent payments from the infant formula divestiture depend on future performance, adding execution risk.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Perrigo is in a strategic turnaround, divesting non‑core businesses while focusing on core consumer self‑care products.

Company-level read

Ticker impact

$PRGOBullishHigh confidence
Context

Q3 2026 earnings beat EPS expectations and showed margin improvement, prompting a 4.6% stock rise.

Expected impact

likely continued upside as the market rewards the turnaround progress and EPS beat.

Evidence & confidence

EPS beat, margin expansion, and progress on divestitures signal improving fundamentals, supporting further price gains.

Market effects

Sector

Consumer self‑care sector may see renewed investor interest as Perrigo's turnaround gains traction.

Regional

U.S. OTC and European OTC markets could benefit from perceived recovery in consumer health demand.

Global

Modest impact; highlights broader trends in health‑care consumer products.

Counterpoint

What could challenge this read

The revenue miss and ongoing category headwinds could limit upside if turnaround stalls.

Key entities

  • company
    Perrigo Company plc

    Consumer self‑care manufacturer reporting Q3 2026 results.

Read at source← All news

StoryPerrigo reports Q3 loss, updates outlook and announces Infant Formula divestiture

Also covered by

5 outlets

Related articles

NOV 4
$PRGOMed

Perrigo 2026: Revenue $988.6M, EPS ($0.2) — 10-Q Summary

Perrigo reported 2026 nine-month net sales of $988.6M, down 5.2% YoY, and a net loss of $27.5M, compared to a net income of $7.5M in the prior year. Diluted loss per share was $0.2, versus earnings of $0.05. The decline was attributed to soft consumer demand, lower retailer inventories, and the sale of the Dermacosmetics business. Perrigo plans to sell its Infant Formula business for up to $175M and expects $80M-$100M in annual savings from a two-year efficiency program.

tradingview.com1 min
NOV 4
$PRGOHigh

Perrigo Company Slips To Loss In Q3

Perrigo Company reported Q3 net sales of $989M, down from $1.04B last year. It posted a loss of $14.3M, or $0.10 per share, compared to a profit of $12.7M, or $0.09 per share, in the prior year. Adjusted earnings fell to $0.60 per share from $0.80. The company expects fiscal 2026 adjusted earnings of $2.25 to $2.45 per share. Pre-market, PRGO shares were up 1.02% at $15.84.

rttnews.com1 min
NOV 4
$PRGOMedAI 8/10

Perrigo beats earnings but misses on revenue

Perrigo (PRGO) reported Q3 earnings of $0.60 per share, beating estimates by $0.05, but revenue of $989M missed expectations and fell 5.2% YoY. Full-year 2026 EPS guidance was raised to $2.15-$2.35, above consensus. The company plans to sell its Infant Formula business for up to $175M, expecting an impairment loss of $275M-$375M in Q4. Shares rose 0.89% in pre-market trading.

investing.com1 min
NOV 4
$PRGOMed

Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands • Infant Formula divestiture exp

SEC EDGAR 8-K3 min
NOV 4
$PRGOMedAI 8/10

Perrigo: Q3 Earnings Snapshot

Perrigo (PRGO) reported a Q3 loss of $27.5M, or 20 cents per share, but adjusted earnings of 60 cents beat estimates. Revenue of $988.6M missed expectations. The company forecasts full-year earnings of $2.25-$2.45 per share.

finance.yahoo.com1 min